ERBB2 and neoplasm: To address this issue, we have directly compared the HER2 targeting properties of trastuzumab labeled using [*I]SIB and [*I]SGMIB in HER2-positive BT474 breast carcinoma cells and BT474M1 tumor xenograft models.